Valerie Waters

Molecular epidemiology of gram-negative bacilli from infected neonates and health care workers' hands in neonatal intensive care units.

The effect of cyclosporin A on airway cell proinflammatory signaling and pneumonia.

Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues.

Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia.

Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.

Burkholderia pseudomallei infection in a cystic fibrosis patient from the Caribbean: a case report.

Health benefits of dietary fiber.

Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States.

Outbreak of atypical pertussis detected by polymerase chain reaction in immunized preschool-aged children.

Sputum induction in routine clinical care of children with cystic fibrosis.

Invasive aspergillosis in cystic fibrosis: a fatal case in an adolescent and review of the literature.

Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease.

Epidemiology of borderline oxacillin-resistant Staphylococcus aureus in pediatric cystic fibrosis.

Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis.

Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis.

New treatments for emerging cystic fibrosis pathogens other than Pseudomonas.

Serum galactomannan in cystic fibrosis patients colonized with Aspergillus species.

Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis.

Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Analysis of the cystic fibrosis lung microbiota via serial Illumina sequencing of bacterial 16S rRNA hypervariable regions.

Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.

Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.

Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients.

Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients.

Guidelines for the prevention and management of community-associated methicillin-resistant Staphylococcus aureus: A perspective for Canadian health care practitioners.

Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients.

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis.

Incompatibility of ciprofloxacin and meropenem injections.

Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis.

Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Editorial commentary: how can understanding the phenotype of Pseudomonas aeruginosa lead to more successful eradication strategies in cystic fibrosis?

Inhaled liposomal amikacin.

Is there a role for antimicrobial stewardship in cystic fibrosis?

Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.

Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi.

In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.

Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients.

Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.

Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients.

Cystic fibrosis microbiology: Advances in antimicrobial therapy.

Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.

Lung microbiota across age and disease stage in cystic fibrosis.

Phenotypic diversity within a Pseudomonas aeruginosa population infecting an adult with cystic fibrosis.

Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations.

Selective Sweeps and Parallel Pathoadaptation Drive Pseudomonas aeruginosa Evolution in the Cystic Fibrosis Lung.

An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis.

Activity of Tobramycin against Cystic Fibrosis Isolates of Burkholderia cepacia Complex Grown as Biofilms.

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.

Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients.

Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia.

Pulmonary Exacerbations in Children with Cystic Fibrosis.

Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient.

Infections With Biofilm Formation: Selection of Antimicrobials and Role of Prolonged Antibiotic Therapy.

Heuristic decision-making about research participation in children with cystic fibrosis.

Longitudinal study of Stenotrophomonas maltophilia antibody levels and outcomes in cystic fibrosis patients.

Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis.

Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis.

Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.

Navigating social and ethical challenges of biobanking for human microbiome research.

Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis.

Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection.

Clinical Outcomes Associated with Achromobacter Species Infection in Patients with Cystic Fibrosis.

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.

Optimizing Blood Collection and Processing for Quantiferon-TB Gold in-Tube Testing Gives Low Rates of Indeterminate Results: Clinical Implications.

MexXY efflux pump overexpression and aminoglycoside resistance in cystic fibrosis isolates of Pseudomonas aeruginosa from chronic infections.

Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.

Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment.

Isolated cutaneous mucormycosis in a pediatric renal transplant recipient.

Defining chronic Pseudomonas aeruginosa infection in cystic fibrosis.

Chronic Antibiotic Use in Cystic Fibrosis: A Fine Balance.

Epidemiology of Clonal Pseudomonas aeruginosa Infection in a Canadian Cystic Fibrosis Population.

Burkholderia multivorans septicemia in a pediatric liver transplant patient.

Prevalence of tuberculosis infection and disease in children referred for tuberculosis medical surveillance in Ontario: a single-cohort study.

Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Defining antimicrobial resistance in cystic fibrosis.

Antimicrobial resistance in cystic fibrosis: Does it matter?

Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms.

A genome-wide association analysis reveals a potential role for recombination in the evolution of antimicrobial resistance in Burkholderia multivorans.

Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams.

Microbiome networks and change-point analysis reveal key community changes associated with cystic fibrosis pulmonary exacerbations.

Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review.

Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis.

Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections.

Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices.

ET12 transmission in adults with cystic fibrosis.

Microbiology of Cystic Fibrosis Airway Disease.

Treatment of localized mucormycosis using nasal amphotericin B irrigation in pediatric oncology.

Finding the relevance of antimicrobial stewardship for cystic fibrosis.

Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.

Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.

Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.

Pseudomonas aeruginosa strain sharing in early infection among children with cystic fibrosis.

Antimicrobial resistance: Concerns of healthcare providers and people with CF.

Clinical Outcomes Associated with Complex Infection in Patients with Cystic Fibrosis.

Inguinal mass in a 4-month-old boy.

Lung Clearance Index to Track Acute Respiratory Events in School-age Children with Cystic Fibrosis.

Factors influencing the acquisition and eradication of early Pseudomonas aeruginosa infection in cystic fibrosis.

Choosing Wisely: Computed Tomography in the Diagnosis of Adolescents With Intrathoracic Tuberculosis.

Ecological Succession of Polymicrobial Communities in the Cystic Fibrosis Airways.

Determinants of lung disease progression measured by lung clearance index in children with cystic fibrosis.

Approaches to Targeting Bacterial Biofilms in Cystic Fibrosis Airways.

Evaluation of digital dispense-assisted broth microdilution antimicrobial susceptibility testing for Pseudomonas aeruginosa isolates.

Beneath the surface: assessing cystic fibrosis pulmonary infections in the era of highly effective modulator therapy.

The role of Psl in the failure to eradicate Pseudomonas aeruginosa biofilms in children with cystic fibrosis.

Two Steps Forward: Improving the Management of Cystic Fibrosis Pulmonary Exacerbations.